Nicotinamide and the skin

  title={Nicotinamide and the skin},
  author={Andrew C Chen and Diona L Damian},
  journal={Australasian Journal of Dermatology},
  • A. C. Chen, D. Damian
  • Published 1 August 2014
  • Biology, Medicine
  • Australasian Journal of Dermatology
Nicotinamide, an amide form of vitamin B3, boosts cellular energy and regulates poly‐ADP‐ribose‐polymerase 1, an enzyme with important roles in DNA repair and the expression of inflammatory cytokines. Nicotinamide shows promise for the treatment of a wide range of dermatological conditions, including autoimmune blistering disorders, acne, rosacea, ageing skin and atopic dermatitis. In particular, recent studies have also shown it to be a potential agent for reducing actinic keratoses and… 
Use of nicotinamide in dermatology
The evidence underlying the use of nicotinamide for various dermatological indications, including nonmelanoma cancer prophylaxis, blistering disorders, acne vulgaris and cosmetic indications, is reviewed, and its future role in dermatological practice is speculated upon.
Nicotinamide for Skin-Cancer Chemoprevention.
Nicotinamide (vitamin B3) has a range of photoprotective effects in vitro and in vivo; it enhances DNA repair, reduces UV radiation-induced suppression of skin immune responses, modulates
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety
Nicotinamide prevents ultraviolet radiation from reducing ATP levels and inhibiting glycolysis, thus preventing the UV radiation‐induced energy crisis and enhances DNA repair and reduces UV‐induced suppression of immunity.
Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention
Oral NAM administration reduces the level of UV-mediated immunosuppression and lowers the rate of non-melanoma skin cancers in high-risk patients, suggesting NAM replenishment strategy may be a promising approach for skin cancer chemoprevention.
Nicotinamide: New Indications in Dermatology.
Oral nicotinamide: The role in skin cancer chemoprevention
Efficacy and safety of NAM was evaluated in a Phase III double‐blinded control‐placebo study (ONTRAC), thus demonstrating that the incidence of actinic keratoses and non‐melanoma skin cancers was lower in the nicotinamide group than in placebo group.
Niacinamide improves skin barrier function and therefor can be effective in treating xerosis, atopic dermatitis and rosacea and can be an important adjunctive therapeutic in conditions such as pemphigus vulgaris and psoriasis.
Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma
The rational use of arsenic trioxide, itraconazole, all-trans-retinoic acid and nicotinamide are analyzed as possible adjuvant therapies either in advanced not responding basal cell carcinoma or during follow-up based on Hedgehog pathway.
Oral nicotinamide for non-melanoma skin cancers: A review
Current evidence is not definitive that oral nicotinamide supplementation reduces the incidence of NMSC, but it constitutes a low-risk management option that may be particularly relevant for high-risk individuals, and should be discussed as an option for these patients.
Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers
The current state of the art regarding NNMT role in SC is summarized to support future studies focused on exploring the diagnostic and prognostic potential of NN MT in skin malignancies, as well as its suitability for targeted therapy.


Nicotinamide in dermatology and photoprotection.
The use of nicotinamide for inflammatory dermatoses and photoaging and its emerging role in photoprotection are outlined and its role as a cellular energy precursor, a modulator of inflammatory cytokines, and an inhibitor of the nuclear enzyme poly(adenosine diphosphate-ribose) polymerase-1 are concentrated.
Role of Nicotinamide in DNA Damage, Mutagenesis, and DNA Repair
The role of nicotinamide is examined in the protection from carcinogenesis, DNA repair, and maintenance of genomic stability, as well as a range of cosmetic, hair, and skin preparations.
Nicotinamide-containing sunscreens for use in Australasian countries and cancer-provoking conditions.
Hepatic toxicity from large doses of vitamin B3 (nicotinamide).
The following case demonstrates that nicotinamide may cause major hepatic injury and is associated with abnormalities of liver function when used in large doses in the treatment of hypercholesterolemia.
Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review.
This article reviews the substantial number of reports published over the past 50 years that document the clinical utility and safety of oral and topical formulations of nicotinamide for the treatment of a variety of inflammatory skin conditions.
Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier
Nicotinamide improved the permeability barrier by stimulating de novo synthesis of ceramides, with upregulation of serine palmitoyltransferase (SPT) and other intercellular lipids.
Nicotinamide is a potent inhibitor of proinflammatory cytokines
It is demonstrated that nicotinamide has a potent immunomodulatory effect in vitro, and may have great potential for treatment of human inflammatory disease.
Topical nicotinamide modulates cellular energy metabolism and provides broad‐spectrum protection against ultraviolet radiation‐induced immunosuppression in humans
Nicotinamide (vitamin B3) prevents UV‐induced immunosuppression and carcinogenesis in mice, and solar‐simulated (ss) UV‐ induced immunOSuppression in humans.
Nicotinamide gel provides potent antiinflammatory activity without the risk of inducing bacterial resistance.
Case reports: new onset flushing due to unauthorized substitution of niacin for nicotinamide.
A patient with rosacea is reported who developed new onset flushing due to unauthorized substitution of niacin for nicotinamide, which is a well-known and often dose-limiting side effect of niakin therapy.